+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
Healthy Volunteers
ID07093580

Phase 1 Study of S-892216 Long-acting Injectable in Healthy Adults Evaluating Single and Multiple Doses

Led by Shionogi · Updated on 2026-10-16

128

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety, tolerability, and how the body processes pharmacokinetics a long-acting injectable drug called S-892216-LAI in healthy adults. This Phase 1 trial involves participants aged 18 to 55 years to better understand the effects of single and multiple doses of this investigational drug compared to a placebo. Participants will receive either a single dose of S-892216-LAI or placebo on Day 1 in the first treatment period. In the second treatment period, participants will receive multiple doses on Day 1 and Day 85. The study uses a randomized, parallel design and includes a placebo control with quadruple masking to keep the treatment assignment confidential. During the study, participants will be monitored closely for any treatment-emergent adverse events from Day 1 through up to Day 448, depending on the treatment period. Researchers will measure the drug and its metabolites in the blood at various timepoints to assess concentration levels and how quickly the drug reaches its maximum concentration. Participants will undergo regular evaluations for safety and drug levels over the course of the study, which may last up to approximately 15 months.

CONDITIONS

Brief Title

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

Research Team

S

Shionogi Clinical Trials Administrator Clinical Support Help Line

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here